In a clinical trial of bb2121 (an anti-BCMA CAR-T cell therapy) involving 128 patients with MM (NCT03361748), the objective response rate (ORR) reached 73%, demonstrating the considerable therapeutic potential of targeting BCMA in MM. Here, TNFRSF17 is linked to Miyoshi myopathy.